Medpace Holdings Files 2024 10-K

TL;DR

Medpace 2024 10-K is in. Full financials and ops details for the year ending Dec 31, 2024.

AI Summary

Medpace Holdings, Inc. filed its 2024 10-K on February 11, 2025, reporting on its fiscal year ending December 31, 2024. The company, a commercial contract research organization, operates in the biological research sector. Key financial details and operational metrics for the fiscal year 2024 are presented within this comprehensive filing.

Why It Matters

This filing provides investors and analysts with a detailed overview of Medpace's financial performance and operational status for the 2024 fiscal year, crucial for understanding the company's trajectory and market position.

Risk Assessment

Risk Level: low — The filing is a standard annual report and does not inherently indicate new or elevated risks.

Key Numbers

• 30,466,806 — Shares (Number of shares associated with the filing)

Key Players & Entities

• Medpace Holdings, Inc. (company) — Filer of the 10-K
• 2024-12-31 (date) — Fiscal year end
• 2025-02-11 (date) — Filing date
• 320434904 (dollar_amount) — IRS Number
• DE (company) — State of Incorporation
• 513-579-9911 (dollar_amount) — Business Phone

FAQ

Key Financial Figures

• $0.01 — hange on which registered Common Stock $0.01 par value MEDP Nasdaq Global Select Mar
• $250 million — opharmaceutical companies with at least $250 million in sales, based on publicly available d

Filing Documents

• medp-20241231.htm (10-K) — 1607KB
• medp-20241231xexx211.htm (EX-21.1) — 4KB
• medp-20241231xexx231.htm (EX-23.1) — 2KB
• medp-20241231xexx311.htm (EX-31.1) — 10KB
• medp-20241231xexx312.htm (EX-31.2) — 10KB
• medp-20241231xexx321.htm (EX-32.1) — 5KB
• medp-20241231xexx322.htm (EX-32.2) — 5KB
• medp-20241231_g1.jpg (GRAPHIC) — 90KB
• 0001668397-25-000017.txt ( ) — 9461KB
• medp-20241231.xsd (EX-101.SCH) — 64KB
• medp-20241231_cal.xml (EX-101.CAL) — 99KB
• medp-20241231_def.xml (EX-101.DEF) — 311KB
• medp-20241231_lab.xml (EX-101.LAB) — 804KB
• medp-20241231_pre.xml (EX-101.PRE) — 576KB
• medp-20241231_htm.xml (XML) — 1339KB

Risk Factors

Risk Factors 11 1B. Unresolved Staff Comments 28 1C. Cybersecurity 28 2.

Legal Proceedings

Legal Proceedings 29 4. Mine Safety Disclosures 29 PART II 30 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 30 6. Reserved 32 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 32 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 42 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 44 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 77 9A.

Controls and Procedures

Controls and Procedures 77 9B. Other Information 78 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 78 PART III 79 10. Directors, Executive Officers and Corporate Governance 79 11.

Executive Compensation

Executive Compensation 79 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 79 13. Certain Relationships and Related Transactions, and Director Independence 79 14. Principal Accountant Fees and Services 80 PART IV 81 15. Exhibits and Financial Statement Schedules 81 16. Form 10-K Summary 81 Exhibit Index 82

Signatures

Signatures 84 - 2 - Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts contained herein, including, without limitation, statements regarding our results of operations; financial position and performance; liquidity and our ability to fund our business operations and initiatives; capital expenditure and debt service obligations; business strategies, plans and goals, including those related to marketing, acquisitions and expansion of our business; product approvals and plans; industry trends; general economic conditions, including inflation, interest rates and other pricing pressures that could impact our operating margins; expectations regarding consumer behaviors and trends; our culture and operating philosophy; human resource management; arrangements with and delivery of our services to the customers; conversion of backlog; dividend policy; legal proceedings; and our objectives for future operations, are forward-looking statements. The words "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," "likely", "opportunity," "may," "could," "outlook," "can," "trend," "might," "drives," "hope," "potential," "project," "predict," and similar expressions are intended to identify forward-looking statements. However, the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based largely on our current expectations and projections about future events and financial or other trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Any forward-looking state

Business

Item 1. Business Overview We are one of the world's leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise. We believe this combination results in timely and cost-effective delivery of clinical development services for our customers. We believe that we are a partner of choice for small and mid-sized biopharmaceutical companies based on our ability to consistently utilize our full-service, disciplined operating model to deliver timely and high-quality results for our customers. Accordingly, our business strategy aims to continue to expand our market share in the growing Phase I-IV CRO market as we conduct clinical trials across all major therapeutic areas, with particular strength in Oncology, Metabolic, Cardiology, Antiviral and Anti-infective (AVAI) and Central Nervous System (CNS). Our Revenues: Markets and Clinical Development Services Before a new drug can be commercialized, it often must undergo extensive pre-clinical and clinical testing and regulatory review to verify safety and efficacy. CROs provide a comprehensive range of product development services for Phase I-IV clinical trials. These clinical trials are separated into distinct phases in order to thoroughly evaluate the product. We generate our revenues by providing a full suite of services supporting the entire clinical development process from Phase I to Phase IV across a wide range of therapeutic areas. Medical Department : Our medical department consists of therapeutic leads who provide strategic direction for study design and planning, train

View Full Filing

View this 10-K filing on SEC EDGAR